Guggenheim analyst Seamus Fernandez reiterated a Neutral rating on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst commented: "Yesterday, BAYRY announced Ph3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE